

Jonathan E Koltz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8474041/publications.pdf>

Version: 2024-02-01

106
papers

2,791
citations

279798

23
h-index

182427

51
g-index

107
all docs

107
docs citations

107
times ranked

4179
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044.	3.5	4
2	Activated CLL cells regulate IL-17Fâ€producing Th17 cells in miR155-dependent and outcome-specific manners. <i>JCI Insight</i> , 2022, 7, .	5.0	2
3	Enrollment disparities in non-Hodgkin lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18594-e18594.	1.6	0
4	Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. <i>Leukemia</i> , 2021, 35, 1188-1192.	7.2	2
5	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 626-637.	9.4	41
6	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	4.8	11
7	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	7.2	25
8	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	2.8	12
9	A precision medicine classification for treatment of acute myeloid leukemia in older patients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 96.	17.0	5
10	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. <i>Journal of Hematology and Oncology</i> , 2021, 14, 107.	17.0	6
11	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021, 35, 1037-1052.	7.2	19
12	Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL. <i>Blood</i> , 2021, 138, 2625-2625.	1.4	0
13	Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL. <i>Blood</i> , 2021, 138, 2622-2622.	1.4	0
14	Mutations associated with a 17-gene leukemia stem cell score and the scoreâ€™s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 721-729.	3.5	21
15	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. <i>Leukemia</i> , 2020, 34, 358-368.	7.2	8
16	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ <i>KMT2A</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26340-26346.	7.1	59
17	Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia. <i>Nucleic Acids Research</i> , 2020, 48, e40-e40.	14.5	4
18	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44

#	ARTICLE	IF	CITATIONS
19	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020, 4, 239-251.	5.2	29
20	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2020, 136, 5-7.	1.4	4
21	Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
22	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
23	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1451-1459.	4.1	7
24	Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. <i>Journal of Immunology</i> , 2019, 202, 2924-2944.	0.8	9
25	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	7.2	55
26	CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019, 134, 477-477.	1.4	4
27	The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment. <i>Blood</i> , 2019, 134, 2681-2681.	1.4	1
28	A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7001-7001.	1.6	10
29	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrnas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2019, 134, 2694-2694.	1.4	0
30	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). <i>Blood</i> , 2019, 134, 1247-1247.	1.4	1
31	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. <i>Leukemia</i> , 2018, 32, 1338-1348.	7.2	80
32	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	1.6	682
33	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.	5.2	85
34	Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion. <i>Journal of Immunology</i> , 2018, 201, 1570-1585.	0.8	16
35	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	7.2	33
36	A 17-Genes Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification. <i>Blood</i> , 2018, 132, 289-289.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018, 132, 2767-2767.	1.4	0
38	Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation. <i>Molecular Medicine</i> , 2017, 23, 1-12.	4.4	14
39	Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7035-7035.	1.6	14
40	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7036-7036.	1.6	3
41	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016, 1, .	5.0	29
42	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 2379-2388.	4.1	23
43	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. <i>Clinical Immunology</i> , 2016, 172, 44-51.	3.2	11
44	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	1.4	5
45	Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction. <i>Blood</i> , 2016, 128, 3955-3955.	1.4	3
46	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901.	1.4	42
47	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 216-227.	2.9	15
48	Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 313-316.	0.9	26
49	A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 90-100.	2.9	18
50	TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. <i>Journal of Immunology</i> , 2015, 195, 901-923.	0.8	47
51	Ibrutinib for Transformed Lymphoma; A Report of 4 Patients. <i>Blood</i> , 2015, 126, 5115-5115.	1.4	0
52	Chronic Lymphocytic Leukemia Patients and E μ -TCL1 Mice Share a Phenotype of Functional Granulocyte-like and Dysfunctional Monocyte-like Myeloid Derived Suppressor Cells. <i>Blood</i> , 2015, 126, 614-614.	1.4	0
53	The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones. <i>Blood</i> , 2015, 126, 4149-4149.	1.4	0
54	Primary extranodal marginal zone lymphoma of the endometrium: report of four cases and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3036-44.	0.5	5

#	ARTICLE	IF	CITATIONS
55	CLL Sera Drive Maturation of Normal Monocytes to M2-like Macrophages By Direct and Indirect Mechanisms. <i>Blood</i> , 2014, 124, 1970-1970.	1.4	1
56	Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells. <i>Blood</i> , 2014, 124, 3279-3279.	1.4	0
57	TLR-9 and IL-15-Driven Clonal Expansion of B-CLL Cells. <i>Blood</i> , 2014, 124, 1937-1937.	1.4	0
58	Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1042-50.	0.5	9
59	Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7100-7100.	1.6	2
60	Apparent Involvement Of The Interferon, RNA Processing, and Wnt Signaling Pathways In Monoclonal B Lymphocytosis. <i>Blood</i> , 2013, 122, 4157-4157.	1.4	0
61	A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4129-4129.	1.4	30
62	Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation. <i>Blood</i> , 2013, 122, 2583-2583.	1.4	0
63	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 119-119.	1.4	1
64	Concomitant, T-Independent TLR9-Mediated and BCR-Mediated Activation Provides Signals For Optimal Telomerase Induction In Chronic Lymphocytic Leukemia Cells Regardless Of IGHV Mutation Status. <i>Blood</i> , 2013, 122, 4142-4142.	1.4	0
65	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012, 120, 4802-4811.	1.4	52
66	The Clinical Role of Micrnas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). <i>Blood</i> , 2012, 120, 1387-1387.	1.4	1
67	CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors. <i>Blood</i> , 2012, 120, 3626-3626.	1.4	3
68	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012, 120, 44-44.	1.4	4
69	A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6601-6601.	1.6	1
70	Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2533-2533.	1.6	0
71	A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6526-6526.	1.6	0
72	Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator's choice A subset analysis by prognostic group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6525-6525.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 316-316.	1.4	0
74	CLL Cells Can Diversify, Switch, and Differentiate in Response to Autologous T Cell Stimuli Present in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 315-315.	1.4	0
75	Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. <i>Blood</i> , 2012, 120, 2545-2545.	1.4	4
76	Neutropenic Enterocolitis in Adult Patients with Acute Leukemia: A Single Center Experience. <i>Blood</i> , 2012, 120, 4324-4324.	1.4	31
77	CLL Cell Viability Promoted by Myosin Heavy Chain IIA Exposed Apoptotic Cells is BTK-dependent. <i>Blood</i> , 2012, 120, 1767-1767.	1.4	0
78	Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. <i>Molecular Medicine</i> , 2011, 17, 1374-1382.	4.4	140
79	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 5201-5210.	1.4	110
80	Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). <i>Blood</i> , 2011, 118, 414-414.	1.4	2
81	Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells. <i>Blood</i> , 2011, 118, 975-975.	1.4	4
82	Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,. <i>Blood</i> , 2011, 118, 3454-3454.	1.4	0
83	TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,. <i>Blood</i> , 2011, 118, 3690-3690.	1.4	1
84	Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones. <i>Blood</i> , 2011, 118, 624-624.	1.4	0
85	Cytogenetic, Molecular and Clinical Features Associated with Rare CFBF-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). <i>Blood</i> , 2011, 118, 2514-2514.	1.4	0
86	Gene Set Enrichment Analysis of Ki-67high CLL Clones Suggests Complex Interactions of B-Cell Receptor Signaling and Normal Cell Interactions in the Disease. <i>Blood</i> , 2011, 118, 2833-2833.	1.4	0
87	Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients. <i>Blood</i> , 2011, 118, 2619-2619.	1.4	0
88	Longitudinal Analyses of CXCR4dimCD5brCD19+ Fractions of Chronic Lymphocytic Leukemia Clones Reveal Features Consistent with a Source of Clonal Heterogeneity. <i>Blood</i> , 2011, 118, 804-804.	1.4	9
89	Successful Therapy of Cold Agglutinin Disease Utilizing Rituximab. <i>Blood</i> , 2011, 118, 5271-5271.	1.4	0
90	Retrospective Survival of Patients with Primary Central Nervous System Lymphoma (PCNSL) Treated with Upfront Chemoimmunotherapy (R+MVP) and without Radiation: North Shore - LJJ University Hospital From 2006 to 2011. <i>Blood</i> , 2011, 118, 4958-4958.	1.4	0

#	ARTICLE	IF	CITATIONS
91	ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category. <i>Blood</i> , 2011, 118, 417-417.	1.4	0
92	CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report. <i>Blood</i> , 2011, 118, 254-254.	1.4	0
93	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.	1.4	113
94	Elevated IL-17 Producing Cells (Th17 and Non-Th17) In Different CLL Microenvironments: Correlation with Overall Survival, Prognostic Relevance and Phenotypic Heterogeneity. <i>Blood</i> , 2010, 116, 2442-2442.	1.4	1
95	Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. <i>Blood</i> , 2010, 116, 331-331.	1.4	4
96	Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and MicroRNA (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. <i>Blood</i> , 2010, 116, 577-577.	1.4	2
97	Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients. <i>Blood</i> , 2010, 116, 1392-1392.	1.4	3
98	Detection of Activation-Induced Cytidine Deaminase RNA In CLL Cells Correlates with Shorter Patient Survival and High Numbers of CD38+ Cells. <i>Blood</i> , 2010, 116, 2415-2415.	1.4	0
99	Somatic Hypermutation In Stereotyped Subset 4 BCRs/mAbs of CLL Patients, Expressing IGHV4-34 gene, Edit Anti-DNA Reactivity. <i>Blood</i> , 2010, 116, 2444-2444.	1.4	1
100	Chronic Lymphocytic Leukemia B Cells Variably Express Functional Activation-Induced Cytosine Deaminase Protein. <i>Blood</i> , 2010, 116, 378-378.	1.4	0
101	Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study. <i>Blood</i> , 2010, 116, 98-98.	1.4	0
102	Some CLL Cells Bind Myosin-Exposed Apoptotic Cells. Exposure of Cytoplasmic Myosin Results From Transfer of Caspase-3 Dependent Cleavage Products to the Outer Cell Membrane. <i>Blood</i> , 2010, 116, 3900-3900.	1.4	0
103	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. <i>Blood</i> , 2009, 114, 3615-3624.	1.4	37
104	Elevated Binding of Chronic Lymphocytic Leukemia Antibody to a Subset of Apoptotic Cells with Exposed Non-Muscle Myosin Heavy Chain IIA Correlates with Poor Patient Outcome.. <i>Blood</i> , 2009, 114, 799-799.	1.4	0
105	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. <i>Molecular Medicine</i> , 2008, 14, 665-674.	4.4	174
106	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 755-764.	8.2	515